The Fleming Fund brings evidence and people together to encourage action against drug resistance for a healthier world.

We support low- and middle-income countries (LMICs) to generate, share and use data to improve antimicrobial usage and encourage investment in antimicrobial resistance (AMR).

In April, I delivered my first lecture as Professor of Medical Microbiology at the University of Ghana Medical School. My lecture was…

Colistin is a last-resort antibiotic reserved for the treatment of serious multidrug-resistant infections in humans. Recognising its…

A new report by the Fleming Fund examines the facilitators, barriers, and sustainability challenges associated with antimicrobial…

The Fleming Fund’s Regional Grants programme has been instrumental in tackling antimicrobial resistance (AMR) and addressing the acu…

26: Active Country Grants
20: Active Regional Grants
321: Supported surveillance sites
30: Countries we work in (more than)
170: National Action Plans developed with Fleming Fund support
155: Countries have supplied data on use of antimicrobial medicines in animals to WOAH database

Fleming Fund Learning

Insights from the TrACSS Country Self-Assessment Survey Publication

The sixth and final Fleming Fund Fellows Symposium explored how the fellows' learning and development have made a lasting impact on the…

Tackling antimicrobial resistance (AMR) demands a diverse workforce, spanning a range of disciplines from microbiology to data analysis.…

Antimicrobial resistance (AMR) poses a major global health threat, with low- and middle-income countries in Africa and Asia carrying the…